The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 11, 2020

Filed:

Feb. 09, 2018
Applicant:

The Catholic University of America, Washington, DC (US);

Inventor:

Venigalla B. Rao, Silver Spring, MD (US);

Assignee:

The Catholic University of America, Washington, DC (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/295 (2006.01); A61K 39/385 (2006.01); A61K 39/07 (2006.01); A61K 39/02 (2006.01); C07K 14/24 (2006.01); C07K 14/32 (2006.01); C07K 14/005 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/295 (2013.01); A61K 39/0291 (2013.01); A61K 39/07 (2013.01); A61K 39/385 (2013.01); C07K 14/005 (2013.01); C07K 14/24 (2013.01); C07K 14/32 (2013.01); C07K 19/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/57 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/627 (2013.01); A61K 2039/645 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C12N 2795/00034 (2013.01); C12N 2795/00062 (2013.01); C12N 2795/10122 (2013.01); C12N 2795/10134 (2013.01);
Abstract

Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V fromand PA antigen fromfused in-frame and retaining structural and functional integrity of all three antigens. Another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed with these three antigens on the capsid surface of the bacteriophage nanoparticles. These bivalent immunogenic compositions are able to elicit robust immune response in a subject administered said the bivalent immunogenic compositions and provide protection to the subject against sequential or simultaneous challenge with both anthrax and plague pathogens.


Find Patent Forward Citations

Loading…